Detailed clinical phenotyping and generalisability in prognostic models of functioning in at-risk populations

M Rosen; LT Betz; N Kaiser; N Penzel; D Dwyer; TK Lichtenstein; F Schultze-Lutter; L Kambeitz-Ilankovic; A Bertolino; S Borgwardt; P Brambilla; R Lencer; E Meisenzahl; C Pantelis; RKR Salokangas; R Upthegrove; S Wood; S Ruhrmann; N Koutsouleris; J Kambeitz

Journal article

Detailed clinical phenotyping and generalisability in prognostic models of functioning in at-risk populations

M Rosen, LT Betz, N Kaiser, N Penzel, D Dwyer, TK Lichtenstein, F Schultze-Lutter, L Kambeitz-Ilankovic, A Bertolino, S Borgwardt, P Brambilla, R Lencer, E Meisenzahl, C Pantelis, RKR Salokangas, R Upthegrove, S Wood, S Ruhrmann, N Koutsouleris, J Kambeitz

British Journal of Psychiatry | CAMBRIDGE UNIV PRESS | Published : 2022

DOI: 10.1192/bjp.2021.141

Abstract

Personalised prediction of functional outcomes is a promising approach for targeted early intervention in psychiatry. However, generalisability and resource efficiency of such prognostic models represent challenges. In the PRONIA study (German Clinical Trials Register: DRKS00005042), we demonstrate excellent generalisability of prognostic models in individuals at clinical high-risk for psychosis or with recent-onset depression, and substantial contributions of detailed clinical phenotyping, particularly to the prediction of role functioning. These results indicate that it is possible that functioning prediction models based only on clinical data could be effectively applied in diverse health..

View full abstract

University of Melbourne Researchers

Dom Dwyer Author

Christos Pantelis Author

Stephen Wood Author

Related Projects (1)

NEUROBIOLOGICAL 'RISK' AND 'RESILIENCE' BIOMARKERS OF SEVERE MENTAL ILLNESS

Mental disorders of childhood (schizotypal disorder, autism spectrum disorders) and adolescence (psychoses, schizophrenia) represent a major..

Grants

Awarded by Seventh Framework Programme

Funding Acknowledgements

PRONIA is a Collaboration Project funded by the European Union under the 7th Framework Programme (grant agreement no. 602152). M.R. is supported by a grant from the Koeln Fortune Program/Faculty of Medicine, University of Cologne. R.U. reports grants from the Medical Research Council, grants from the National Institute for Health Research, and personal fees from Sunovion, outside the submitted work. J.K. and N.Ko. received honoraria for talks presented at education meetings organised by Otsuka/Lundbeck. C.P. was supported by a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship (1105825) and an NHMRC L3 Investigator Grant (1196508), has received honoraria for talks at educational meetings and has served on an advisory board for Lundbeck, Australia Pty Ltd.